WOK vs WORX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
WOK presents a classic 'value trap' scenario, characterized by a stable Piotroski F-Score of 6/9 but catastrophic price performance. While the company maintains a low debt-to-equity ratio and a stable health score, it has suffered a near-total loss of market value (-100% over 1Y, 3Y, and 5Y). Negative revenue growth (-14.40%) and negative profit margins (-10.89%) suggest a failing business model despite the superficially low Price-to-Book (0.07) and Price-to-Sales (0.15) ratios.
SCWorx Corp exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. The company is experiencing a catastrophic price collapse, with a 5-year decline of 99.7% and a recent 1-month drop of 47.5%. Despite a low debt-to-equity ratio and modest revenue growth of 13.8%, the profit margin of -154.44% and an ROE of -76.35% demonstrate an unsustainable business model that is rapidly eroding shareholder equity.
Compare Another Pair
Related Comparisons
WOK vs WORX: Head-to-Head Comparison
This page compares WORK Medical Technology Group LTD (WOK) and SCWorx Corp. (WORX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.